This Week in SICKLE cell News FEBRUARY 22nd-28th

By Sean Marshall
This week the highlight would be a report from Grand View research outlining. The article produces by News Wire explained how the world Hemoglobin market will only raise in value. If the predictions are correct revenue due to research and cures towards blood born diseases will be expected to reach a U.S. dollar of “8.82 million.”
The article explains that this is all due to a realization that blood born illnesses are increasing in recent years and there are still no real solutions. The article goes so far as to explain that the “rising prevalence of hemoglobin disorders such as sickle cell anemia, thalassemia, Hb C, and Hb E is estimated to be the high impact rendering drivers of the market.” It was also explained that “according to the WHO, hemoglobin disorders are endemic in over 60% of 229 countries affecting over 70% of births. It is also reported that minimum 5% of the world population are carriers of significant variation.”
The article also tackle issues that can cause complication to those with sickle cell disease as well as where sickle cell disease and other blood diseases. These factors included low level hygiene, low awareness levels and the inability to get to proper medical facilities.
Three important facts that the article highlighted about sickle cell that should be passed on were:
“The market for Sickle Cell Disease (SCD) was the largest with revenue valued at over USD 2,290.0 million in 2014. Rising prevalence of hemoglobinopathies and presence of strong product pipeline for sickle cell anemia such as HQK-1001 and Luspatercept are growth promoting factors of this market.”
“Genetic testing for diagnosis of sickle cell disorders is expected to witness lucrative growth over the forecast period. It is estimated to grow at a CAGR of around 7.0%. Increasing awareness levels among people coupled with government programs such as the National Sickle Cell Disease Control Program conducted by the WHO in Africa are anticipated to enhance the usage rates for diagnostic tests pertaining to SCD”
“Hydroxyurea was one of the dominating segments of the SCD therapy market owing to the presence of the FDA-approved drugs such as Droxia and Hydrea by Bristol Myers Squib. SCD. Thalassemia market holds an extensive product portfolio in pipeline and their expected commercialization is anticipated to drive market growth. For instance, The Ellis Lab is developing a gene therapy for SCD in collaboration with Dr.Victor Garcia.”

The original article is fantastic and should be read in detail. What I have presented is only a small portion of what I personally feel is important. I would highly recommend anyone in the sickle cell community or any blood born illness community to read the Grand view researching report or in the very least a news outlet reporting on it.
PR News wire’s article on Grandview's research can be found here: http://www.prnewswire.com/news-releases/hemoglobinopathies-market-worth-88-billion-by-2022-grand-view-research-inc-569930631.html